Novel therapies in SLE treatment: A literature review. (PubMed, Adv Clin Exp Med) - Jan 16, 2025 - "For a long time, European Alliance of Associations for Rheumatology (EULAR) recommended only 2 biological agents in the treatment of SLE: belimumab and rituximab. However, in 2023, anifrolumab, an interferon (IFN) receptor inhibitor, and voclosporin, a novel calcineurin inhibitor, appeared in new SLE treatment guidelines. In addition, several biological agents are targeting different cells or cytokines that are being evaluated in phase II and III clinical trials. Apart from that, experimental therapies such as targeting of plasma cells, chimeric antigen receptor T-cell therapy (CAR-T) or stem cell transplantation appear promising in the treatment of the severe forms of SLE."
Journal • Review • Bone Marrow Transplantation • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus • Transplantation
|
|
Jakub A Mastalerz; Magdalena Szmyrka; Mateusz Sydor; Wojciech Plizga
|